Itamar Medical (TASE:ITMR), the leader in non-invasive vascular health diagnostics, announced today that an agreement has been signed with Roche (SIX:RO, ROG; OTCQX:RHHBY) by which Itamar will develop an EndoPAT device designated for use with animal models, enabling pre-clinical studies examining the efficacy of various compounds in the early stage of drug development essential for later stage development in humans. Itamar's EndoPAT device is a non-invasive technology designed to diagnose and monitor endothelial dysfunction, which constitutes an early stage of cardiovascular diseases in humans. "Following on from our work with Roche in clinical studies, we are pleased to further our collaboration that will reinforce our strategy of EndoPAT playing a major role in developing personalized medicine and companion diagnostics," said Dr. Dov Rubin, Itamar Medical's President and CEO.
“This advanced development positions the EndoPAT to be the technology of choice to assess endothelial dysfunction in cardiovascular drugs development from the early animal model through the different clinical phase trials in humans.”
"EndoPAT offers the only non-invasive, FDA-cleared technology for detecting endothelial dysfunction that is easily applied and totally operator independent in humans," said Dr. Koby Sheffy, Itamar Medical's CTO and Senior Vice President. "This advanced development positions the EndoPAT to be the technology of choice to assess endothelial dysfunction in cardiovascular drugs development from the early animal model through the different clinical phase trials in humans."
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder